Reimbursement can kill a good device.
It doesn't have to kill yours.
A device can be FDA-approved, clinically effective, and still fail — no code, no coverage, or payment that doesn't cover its cost. Ascalon Market Access finds those problems while they can still be solved.
Does a defensible code describe your procedure — or is there a gap that changes your timeline?
What do Medicare and the major payers say today — and what evidence would change it?
Does the payment actually cover your device — or does the hospital lose money using it?
Full reimbursement requires all three. Most companies find out one is missing later than they should.
Twenty years inside Abbott, Boston Scientific, and Zimmer — now working for you.
Ascalon Market Access is an independent consultancy serving medical device companies and their investors, led by Steve St George — a reimbursement leader who managed coding, coverage, and payment strategy for entire device portfolios before bringing that judgment to companies that can't yet hire it in-house.
Client Result
A coding conclusion that held up through acquisition due diligence.
When a market incumbent told customers the codes couldn't be used with a new competing device, Ascalon's word-by-word analysis found nothing in the code language supporting the claim. The client's trial proceeded on schedule — and the analysis held through acquisition review.
Find out where your device stands.
Every engagement starts the same way: a straight answer about your reimbursement landscape — opportunities, barriers, and what to do next. Fixed fee, scoped in a 30-minute conversation.